References
- Lubitz CC, Economopoulos KP, Pawlak AC, et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid 2014;24:958-65
- Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-22
- Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid 2014;24:472-9
- Vigneri R, Malandrino P, Vigneri P. The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 2014;27(1):1-7
- Brito JP, Morris JC, Montori VM. Thyroid cancer: Zealous imaging has increased detection and treatment of low risk tumours. BMJ 2013;347:f4706
- Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 2013;23:885-91
- Ahn HC, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”-Screening and overdiagnosis. New Engl J Med 2014;371:1765-7
- Brito JP. New Research on papillary thyroid carcinoma. American Thyroid Association Annual Meeting. Presented at 84th Annual Meeting of Americn Thyroid Association (ATA); Coronado, California; 2014
- Valle LA, Kloos RT. The prevalence of occult medullary thyroid carcinoma at autopsy. J Clin Endocrinol Metab 2011;96:E109-13
- Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980-7. discussion 987-988
- Lee C. New research on papillary thyroid carcinoma. Presented at 84th Annual Meeting of Americn Thyroid Association (ATA); Coronado California; 2014
- Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24:27-34
- Nilubol N, Kebebew E. Should small papillary thyroid cancers be observed? Apopulation -based study. Cancer 2015;121:1017-24
- Richards ML. Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid 2010;20:707-13
- Richards ML. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer. Surg Oncol Clin N Am 2009;18:39-52
- Marques P, Ratao P, Salgado L, Bugalho MJ. Thyroid carcinoma detected by 18F-fluorodeoxyglucose positron emission tomography among individuals without prior evidence of thyroid disease: relevance and clinicopathological features. Endocrine Practice 2014;1-19
- Pak K, Cheon GJ, Lee KE, et al. Incidental thyroid cancer detected by (18)F-FDG PET: does it have different clinicopathological features? Nucl Med Commun 2014;35:453-8
- Hay ID, Lee RA, Davidge-Pitts C, et al. Long-term outcome of ultrasound-guided percutaneous ablation of selected “recurrent” neck nodal metastasesw1n25 patients with TNM stages III or IVA papillary thyroid carcinoma previouly treated by surgery and 131-I therapy. Surgery 2013;154:1448-54
- Yang K, Wang H, Liang ZY, et al. BRAF(V600E) mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med 2014;39:675-9
- Melo M, Da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metabol 2014;99:E754-65
- Mussazhanova Z, Matsuda K, Naruke Y, et al. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcioma: association with BRAFV600E mutation status. Histopathology 2013;63:726-34